UNSPSC 51191526: Aditeren

This classification denotes a diuretic with the molecular formula C13H17N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L4F80M873G, chemically known as 2,4-diamino-5-(4-amino-3,5-dimethoxybenzyl)pyrimidine but generally known as aditeren, which bears US NIH Compound Identifier 176875. European Medicines Agency schedules Aditeren in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05274MIG.

UNSPSC 51191526 Aditeren, a Commodity code, represents chemical supply products for water treatment and pharmaceutical distribution in state and local government operations. Recent solicitations under this code span water pollution control facilities procuring treatment chemicals and multi-state cooperative purchasing alliances acquiring pharmaceutical and over-the-counter products for distribution across state and local health and human services facilities. The work involves supply of specified chemical commodities and pharmaceutical products with detailed product specifications, pricing structures, and delivery schedules to support ongoing municipal water treatment operations and regional public health inventory systems.

State and local issuing bodies range from individual municipalities to multi-state cooperative purchasing vehicles. The City of Meriden, Connecticut, issued an IFB for sodium bisulfite chemical supply to its Water Pollution Control Facility with a response deadline of July 29, 2026 (Solicitation B027-15). The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026 (Solicitation S1070000015802), with awarded vendors to be distributed to authorized wholesalers effective July 1, 2026 and contract terms extending through June 30, 2028 for existing responders. Recent activity is concentrated in the Northeast and Upper Midwest, with Connecticut and Minnesota representing documented procurement activity. Vendors responding to pharmaceutical RFPs must maintain compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), and must hold comprehensive insurance including commercial general liability of $5,000,000 per occurrence.